Date: 2011-12-06
Type of information: R&D agreement
Compound: technology platform rePAX™
Company: Redbiotec (Switzerland) Intercell (Austria)
Therapeutic area: Infectious diseases
Type agreement: R&D
Action mechanism: With the rePAX™ technology, Redbiotec can copy viruses (or parts of them) as nature-like virus-like particles (VLPs), which are functional but non-replicating and therefore non-hazardous. Through this, all viral diseases are addressable.
Disease: undisclosed viral diseases
Details: Redbiotec has entered into a cooperation with Intercell AG (Vienna, Austria), in which Redbiotec will apply its proprietary technology platform rePAX™ to an undisclosed discovery area .
Financial terms:
Latest news:
